KNIGHT CANCER Institute
OHSU

Brian J. Druker, M.D.
Director, Knight Cancer Institute
Associate Dean for Oncology, School of Medicine
JELD-WEN Chair of Leukemia Research

tel 503 494-5596
fax 503 494-3688

drukerb@ohsu.edu
www.ohsu.edu

Mail Code: KR-HEM
3181 S.W. Sam Jackson Park Rd.
Portland, OR 97239

October 11, 2022

Janusz Maria Sowadski Ph.D.
Founder & Chief Scientific Officer
DNA SEQ Alliance

Dear Janusz,

I am writing to express my steadfast support for your and the DNA SEQ Alliance's efforts to develop a novel family of kinase inhibitors. DNA SEQ's machine learning algorithms' analyses of kinase x-ray structures, including BCR-ABL, identified a novel DFG INTER conformation of kinases. This important discovery, as disclosed in DNA SEQ's 2015 patent application, has defined methods of identification of the DFG INTER conformation and was later awarded two additional U.S. patents.

Discovery of DFG INTER conformation of co-crystals of various kinases using a random forest algorithm has been recently confirmed by nuclear magnetic resonance (NMR). NMR analysis of the ABL protein kinase clearly demonstrated the existence of the DFG INTER conformation in this kinase. The DFG INTER kinase conformation represents a novel target for kinase inhibition and if successful, would create a unique paradigm for a new platform of oncogenic kinase inhibition.

I am committed to this project and would like to offer my assistance. I will help the DNA SEQ Alliance identify potential sources of funding, including angel investors and venture capital sources. Furthermore, once DNA SEQ's molecules reach a certain stage of maturity and IND data is at the development stage, the Knight Cancer Institute at Oregon Health & Science University would be interested in partnering with DNA SEQ in leading Phase One clinical trials.

Sincerely,

Brian J. Druker, M.D .